Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 TrialPeter Bader, Christina Peters, Hermann Kreyenberg et al.|Journal of Clinical Oncology|2015Cited by 132
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosisLennart Lenk, Denis M. Schewe, Matthias Peipp et al.|Blood|2024Cited by 20
Genome‐wide analysis of acute leukemia and clonally related histiocytic sarcoma in a series of three pediatric patientsMatthias Bleeke, Ingo Müller, Pascal D. Johann et al.|Pediatric Blood & Cancer|2019Cited by 10
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targetsJessica I. Hoell, Roland Meisel, Sebastian Ginzel et al.|Blood Advances|2019Cited by 8
Update on long-term outcomes of a cohort of patients with TCF3::HLF positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantationAida Zečkanović, Jean‐Pierre Bourquin, Brice Mouttet et al.|Haematologica|2025Cited by 3